Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that morbilliform rash was the most common adverse cutaneous drug reaction, and antimicrobials, particularly nevirapine, were the primary causative agents among patients in Rajkot, Gujarat.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This case series found that patients with the NUDT15 415C>T variant experienced severe azathioprine toxicity, suggesting genotype-based dosing could reduce adverse effects.

This case report describes a 27-year-old kidney transplant recipient with end stage renal failure who developed infections and adverse reactions, ultimately resolving with antiviral treatment targeting HHV6.

This review outlines the strategies for managing TB-IRIS in HIV patients, emphasizing early detection, prevention, and appropriate treatment to reduce morbidity and mortality.

This article summarizes dermatologic adverse events in patients treated with afatinib in clinical trials and discusses strategies for managing these side effects, without providing new clinical results.

In this study, researchers used a UV-Vis Spectrophotometer to qualitatively and quantitatively analyze Dutasteride residues in human plasma, achieving a total recovery rate of 64.992%, and determined that the BTB reagent effectively selected compounds not analyzed in their research.

This article discusses dutasteride, a new drug for managing benign prostatic hyperplasia, and highlights the need for further experience to confirm its safety and efficacy.

This study introduced a new spectrofluorometric method using a synthesized organic fluorophore to effectively analyze darolutamide and thalidomide in pharmaceutical preparations and biofluids.

This study reported that peginterferon alpha-2a showed high early and sustained virologic response rates in Albanian hemodialyzed patients with hepatitis C, despite causing several adverse effects.

This study reports that drug repurposing for COVID-19 has had mixed results, with success for some drugs but a lack of clinical efficacy for others, highlighting the need for improved preclinical profiling and a standardized drug development platform for future antiviral treatments.

In these initial clinical studies, NAP monotherapy showed significant reductions in HBsAg levels among patients with chronic HBV, suggesting potential as part of future combination therapies.

This case report describes a patient with a NUDT15 minor variant who experienced severe myelosuppression due to azathioprine, emphasizing typical symptoms as clues to the adverse reaction.

This study identified several compounds, including Pictilisib and Nimorazole, that may have higher binding affinity for SARS-CoV-2 main protease than existing inhibitors, potentially offering new treatment alternatives for Covid-19.

Androgen lowering medications don't significantly change HCV-related liver cancer risk in men.

This review highlights that deucravacitinib, a selective TYK2 inhibitor, shows promise as an effective treatment for psoriasis and other inflammatory skin diseases, though real-world evidence beyond psoriasis is still emerging.

This study reports that a novel Nano-Structured Lipid Carrier system for delivering dutasteride may enhance its anticancer effects while reducing systemic side effects in clinical settings.

This study found that bis-benzylisoquinoline and Amaryllidaceae alkaloids, especially aromoline, show potential as antiviral agents, suggesting they could serve as foundations for developing new treatments against coronaviruses by enhancing the understanding of their structure-activity relationships.

This study analyzed post-marketing data from the U.S. FDA Adverse Event Reporting System and identified both known and new safety concerns for Avacopan, an anti-neutrophil cytoplasmic antibodies-associated vasculitis treatment, emphasizing the need for monitoring during early treatment stages.

This study found an increased risk of asthma and allergic rhinitis in individuals with hidradenitis suppurativa.

In this case report, researchers observed hair regrowth in a patient with alopecia universalis and psoriasis after treatment with deucravacitinib, a TYK2 inhibitor, though they note spontaneous regrowth cannot be ruled out and suggest further controlled studies to evaluate its effects on alopecia areata.

In this bibliometric study, researchers analyzed 96 publications from 2000 to 2022 to identify trends in HIV-1 capsid inhibitor research, highlighting the USA as a leading contributor and emphasizing the importance of molecular studies and drug discovery in advancing antiretroviral therapy.

This review discusses various presentations of drug-induced cutaneous eruptions, particularly those associated with interferon and ribavirin, and reports no new clinical findings.

In this study, researchers discovered that several compounds, including brequinar and 6-azauridine, exhibit significant anti-Zika virus activity using a high-throughput screen assay.

This study found that orally administering the CCR5 inhibitor Maraviroc improved hair loss in 4 out of 5 mice with alopecia areata and also reduced the development of the condition, evidenced by decreased CCR5+ T-cell infiltration in treated mice.

This study identified diltiazem, a calcium channel blocker for hypertension, as a promising repurposed treatment for influenza, enhancing antiviral efficacy when combined with oseltamivir.

In this retrospective study, combining TACE with Donafenib showed promising results as a first-line treatment for Chinese patients with unresectable hepatocellular carcinoma, yielding a median progression-free survival of 12.8 months and a one-year overall survival rate of 87.5%, along with a favorable safety profile.

This study identified five FDA-approved drugs, including cepharantine and clofazimine, as potential COVID-19 therapies through in silico and in vitro screening targeting viral entry mechanisms.

This study found that some synthesized heterocyclic derivatives showed promising 5α-reductase inhibitor, antiviral, and anti-tumor activities, surpassing several reference drugs in effectiveness.

This study found that PNU 157706 is a highly potent inhibitor of human 5α-reductase enzymes, showing a stronger and longer-lasting antiprostatic effect in rats compared to finasteride.